One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice
In this retrospective cohort study of 3389 patients with obesity, weight reduction at 1 year was associated with the medication's active agent, its dosage, treatment indication, persistent medication coverage, and patient sex. Future research should focus on identifying the reasons for discontinuation of medication use and interventions aimed at improving long-term persistent coverage.
Authors
- Michael B. Rothberg (ORCID: https://orcid.org/0000-0002-2063-1876)
- Phuc Le (ORCID: https://orcid.org/0000-0003-4788-773X)
- Elizabeth R. Pfoh (ORCID: https://orcid.org/0000-0003-3485-260X)
- Winfield Scott Butsch (ORCID: https://orcid.org/0000-0001-7137-9423)
- Hamlet Gasoyan (ORCID: https://orcid.org/0000-0002-1627-9777)
- Rebecca Schulte (ORCID: https://orcid.org/0000-0002-0009-8947)
Institutions
- Cleveland Clinic (US)
- Cleveland Clinic Lerner College of Medicine (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.33326
- Citations
- 50
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 17.88